All In Biotech

Drug Trial Radar · NCT01408303

[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL

A 6-Week, Randomized, Double-Blind, Placebo(Olive Oil)-Controlled Study to Assess the Efficacy and Safety of Add-On Epanova® to Statin Therapy in Subjects With Persistent Hypertriglyceridemia and High Risk for Cardiovascular Disease

Last checked: Nov 20, 2026Latest source record: Dec 5, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 646 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

646

Actual

Start

Aug 2011

Primary completion

Jun 2012

Study completion Jun 2012

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Omthera Pharmaceuticals, Inc; Medpace, Inc.
First posted
Aug 3, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to evaluate the efficacy of adding Epanova (2 g or 4 g daily) to an optimal statin monotherapy for lowering non-high-density lipoprotein (non-HDL) cholesterol in subjects with persistent hypertriglyceridemia and high risk for cardiovascular disease.

Conditions

  • Hypertriglyceridemia
  • Cardiovascular Disease

Interventions

  • Olive oil, 4gDrug

    Olive oil: 4 x 1 g capsule daily for 6 weeks + prescription statin

  • omega-3-carboxylic acids, 2gDrug

    Epanova: 2 x 1 g capsule + olive oil 2 x 1 g capsule daily for 6 weeks + prescription statin

  • omega-3-carboxylic acids, 4gDrug

    Epanova: 4 x 1 g capsule daily for 6 weeks + prescription statin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Serum Non-HDL CholesterolTime frame: 6 weeks

Locations

89 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Muscle Shoals, Alabama

  • Site not named

    Chandler, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Encinitas, California

  • Site not named

    Lomita, California

  • Site not named

    Los Angeles, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    Spring Valley, California

  • Site not named

    Westlake Village, California

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Brandon, Florida

  • Site not named

    Clearwater, Florida

  • Site not named

    Coral Gables, Florida

  • Site not named

    Hialeah, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Jupiter, Florida

  • Site not named

    Melbourne, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami, Florida

  • Site not named

    New Port Richey, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Oviedo, Florida

  • Site not named

    Ponte Vedra, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Addison, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Oakbrook Terrace, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Newton, Kansas

  • Site not named

    Wichita, Kansas

  • Site not named

    Wichita, Kansas

  • Site not named

    Louisville, Kentucky

  • Site not named

    Madisonville, Kentucky

  • Site not named

    Auburn, Maine

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.